Promising Data on JuxtaFlow Renal Assist Device

The medical device company Roivios shared clinical data from the BIPASS-AKI Feasibility Study of the JuxtaFlow Renal Assist Device (RAD) at the Society of Thoracic Surgeons Perioperative Care Conference. The findings were presented by Evelio Rodriguez, MD, chief of cardiothoracic surgery at Ascension Saint Thomas Hospital in Nashville, Tennessee, at a poster session.

The study supported the potential of JuxtaFlow RAD to enhance kidney function after cardiac surgery with cardiopulmonary bypass, a critical advancement for patients with existing kidney impairment. Patients with CKD undergoing cardiac surgery have incidence rates of acute kidney injury (AKI) up to 50% or more.

Only two of 10 patients treated with the RAD experienced a postoperative AKI, and one case was the result of a protocol deviation. The RAD was found to be safe, with no cases of gross hematuria and no adverse events linked to the device’s active energy.

The study marks the first use of the JuxtaFlow RAD in a surgical setting.